Skip to main content
NASDAQ:DCPH

Deciphera Pharmaceuticals News Headlines

$32.73
-0.28 (-0.85 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.77
$33.84
50-Day Range
$32.91
$47.95
52-Week Range
$31.77
$68.40
Volume488,261 shs
Average Volume454,477 shs
Market Capitalization$1.90 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.49

Headlines

Deciphera Pharmaceuticals (NASDAQ DCPH) News Headlines Today

SourceHeadline
Deciphera Pharmaceuticals (NASDAQ:DCPH) PT Lowered to $75.00 at HC WainwrightDeciphera Pharmaceuticals (NASDAQ:DCPH) PT Lowered to $75.00 at HC Wainwright
marketbeat.com - May 11 at 8:40 AM
HC Wainwright Lowers Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target to $75.00HC Wainwright Lowers Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target to $75.00
marketbeat.com - May 5 at 11:24 AM
Near a 2-Year Low, Is Deciphera Pharmaceuticals a Buy?Near a 2-Year Low, Is Deciphera Pharmaceuticals a Buy?
msn.com - May 13 at 10:15 AM
Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month Low After Analyst DowngradeDeciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month Low After Analyst Downgrade
americanbankingnews.com - May 11 at 6:22 PM
Deciphera Pharmaceuticals (NASDAQ:DCPH) PT Lowered to $75.00Deciphera Pharmaceuticals (NASDAQ:DCPH) PT Lowered to $75.00
americanbankingnews.com - May 11 at 8:37 AM
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2021 Results - Earnings Call TranscriptDeciphera Pharmaceuticals, Inc. (DCPH) CEO Steven Hoerter on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 8:02 AM
Analysts Issue Forecasts for Deciphera Pharmaceuticals, Inc.s Q2 2021 Earnings (NASDAQ:DCPH)Analysts Issue Forecasts for Deciphera Pharmaceuticals, Inc.'s Q2 2021 Earnings (NASDAQ:DCPH)
americanbankingnews.com - May 7 at 8:52 AM
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Forecasted to Earn Q2 2021 Earnings of ($1.17) Per ShareDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Forecasted to Earn Q2 2021 Earnings of ($1.17) Per Share
americanbankingnews.com - May 7 at 8:52 AM
SVB Leerink Research Analysts Decrease Earnings Estimates for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)SVB Leerink Research Analysts Decrease Earnings Estimates for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
americanbankingnews.com - May 6 at 11:42 AM
Jefferies Financial Group Weighs in on Deciphera Pharmaceuticals, Inc.s FY2024 Earnings (NASDAQ:DCPH)Jefferies Financial Group Weighs in on Deciphera Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:DCPH)
americanbankingnews.com - May 6 at 11:42 AM
Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target Cut to $75.00Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target Cut to $75.00
americanbankingnews.com - May 5 at 3:27 PM
Deciphera Pharmaceuticals (NASDAQ:DCPH) Given New $65.00 Price Target at BarclaysDeciphera Pharmaceuticals (NASDAQ:DCPH) Given New $65.00 Price Target at Barclays
americanbankingnews.com - May 5 at 10:24 AM
Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target Cut to $60.00Deciphera Pharmaceuticals (NASDAQ:DCPH) Price Target Cut to $60.00
americanbankingnews.com - May 5 at 9:50 AM
Deciphera Pharmaceuticals (NASDAQ:DCPH) Announces  Earnings Results, Beats Expectations By $0.03 EPSDeciphera Pharmaceuticals (NASDAQ:DCPH) Announces Earnings Results, Beats Expectations By $0.03 EPS
americanbankingnews.com - May 4 at 11:30 PM
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue EstimatesDeciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 4 at 7:26 PM
Deciphera Pharmaceuticals earnings preview: what Wall Street is expectingDeciphera Pharmaceuticals earnings preview: what Wall Street is expecting
markets.businessinsider.com - May 2 at 6:46 PM
Head-To-Head Analysis: Medicure (OTCMKTS:MCUJF) and Deciphera Pharmaceuticals (NASDAQ:DCPH)Head-To-Head Analysis: Medicure (OTCMKTS:MCUJF) and Deciphera Pharmaceuticals (NASDAQ:DCPH)
americanbankingnews.com - May 2 at 8:16 AM
Deciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences SummitDeciphera Pharmaceuticals, Inc. to Present at the Truist Securities Life Sciences Summit
in.finance.yahoo.com - April 29 at 8:26 AM
Deciphera Pharmaceuticals (NASDAQ:DCPH)  Shares Down 2.6% Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Down 2.6%
americanbankingnews.com - April 23 at 11:58 AM
James Arthur Bristol Sells 5,300 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) StockJames Arthur Bristol Sells 5,300 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Stock
americanbankingnews.com - April 21 at 4:48 PM
Deciphera Pharmaceuticals, Inc. (DCPH) Surges 8.8%: Is This an Indication of Further Gains?Deciphera Pharmaceuticals, Inc. (DCPH) Surges 8.8%: Is This an Indication of Further Gains?
finance.yahoo.com - March 22 at 10:52 AM
DCPH Mar 2021 30.000 putDCPH Mar 2021 30.000 put
au.finance.yahoo.com - March 3 at 9:27 AM
DCPH Mar 2021 50.000 putDCPH Mar 2021 50.000 put
au.finance.yahoo.com - March 2 at 11:54 PM
Decipheras Ripretinib In 2nd Line GIST: An AssessmentDeciphera's Ripretinib In 2nd Line GIST: An Assessment
seekingalpha.com - February 19 at 5:12 AM
Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare ConferenceDeciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference
finance.yahoo.com - February 18 at 7:34 AM
Analysts Are Betting On Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) With A Big Upgrade This WeekAnalysts Are Betting On Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) With A Big Upgrade This Week
nasdaq.com - February 14 at 12:36 PM
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
nasdaq.com - February 12 at 1:12 PM
Deciphera (DCPH) Reports Narrower-Than-Expected Q4 LossDeciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss
finance.yahoo.com - February 10 at 12:23 PM
Deciphera Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call PresentationDeciphera Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - February 10 at 5:11 AM
Recap: Deciphera Pharmaceuticals Q4 EarningsRecap: Deciphera Pharmaceuticals Q4 Earnings
finance.yahoo.com - February 9 at 9:22 PM
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial ResultsDeciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 9 at 4:22 PM
Baudax (BXRX) to Report Q4 Earnings: Whats in the Cards?Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?
finance.yahoo.com - February 8 at 12:38 PM
Investors Who Bought Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Three Years Ago Are Now Up 97%Investors Who Bought Deciphera Pharmaceuticals (NASDAQ:DCPH) Shares Three Years Ago Are Now Up 97%
finance.yahoo.com - February 8 at 7:33 AM
Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology DayDeciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day
finance.yahoo.com - February 4 at 8:37 AM
DCPH Feb 2021 70.000 putDCPH Feb 2021 70.000 put
ca.finance.yahoo.com - January 27 at 7:12 PM
DCPH Feb 2021 45.000 putDCPH Feb 2021 45.000 put
ca.finance.yahoo.com - January 26 at 6:48 PM
DCPH Crosses Below Key Moving Average LevelDCPH Crosses Below Key Moving Average Level
nasdaq.com - January 6 at 1:24 PM
DCPH Jan 2021 55.000 putDCPH Jan 2021 55.000 put
au.finance.yahoo.com - December 24 at 12:56 AM
DCPH Stock Forecast: Where Do Hedge Funds Stand?DCPH Stock Forecast: Where Do Hedge Funds Stand?
finance.yahoo.com - December 20 at 10:32 PM
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera PharmaceuticalsThe Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
finance.yahoo.com - December 18 at 1:26 PM
DCPH Dec 2020 50.000 putDCPH Dec 2020 50.000 put
ca.finance.yahoo.com - December 10 at 10:43 PM
Deciphera completes enrollment in late-stage study of ripretinib in GIST patientsDeciphera completes enrollment in late-stage study of ripretinib in GIST patients
seekingalpha.com - November 30 at 9:21 AM
The Boston Globe Names Deciphera a Top Place to Work for 2020The Boston Globe Names Deciphera a Top Place to Work for 2020
finance.yahoo.com - November 23 at 7:56 AM
Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual MeetingDeciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
finance.yahoo.com - November 11 at 7:58 AM
Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual MeetingDeciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting
finance.yahoo.com - November 11 at 7:58 AM
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare ConferenceDeciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference
businesswire.com - November 10 at 7:18 AM
Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3
finance.yahoo.com - November 9 at 1:19 PM
New Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution AgreementNew Drug for Gastrointestinal Stromal Tumours (GIST) to be Launched in Australia, New Zealand and South East Asia Following Distribution Agreement
markets.businessinsider.com - November 5 at 6:51 PM
Deciphera Pharmaceuticals EPS beats by $0.18, beats on revenueDeciphera Pharmaceuticals EPS beats by $0.18, beats on revenue
seekingalpha.com - November 5 at 6:51 PM
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial ResultsDeciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results
finance.yahoo.com - November 5 at 6:51 PM
Deciphera Pharmas QINLOCK shows sustained benefit in gastrointestinal tumorDeciphera Pharma's QINLOCK shows sustained benefit in gastrointestinal tumor
seekingalpha.com - September 18 at 9:27 AM
Decipheras rebastinib shows encouraging efficacy in ovarian cancerDeciphera's rebastinib shows encouraging efficacy in ovarian cancer
seekingalpha.com - September 17 at 8:11 AM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.